#	Pagina
attuale pagina	/open-h2020/projects/225155/index.html

Opendata, web and dolomites

TEXAD SIGNED

TEXAD – Tailoring EXosomes for Autoimmune Diseases

Total Cost €

EC-Contrib. €

Partnership

Views

TEXAD project word cloud

Explore the words cloud of the TEXAD project. It provides you a very rough idea of what is the project "TEXAD" about.

evs treatment umbilical extracellular cells regarding inflammatory ad 101 safer efficacy released responsible platform secondary team secrete million therapeutic prevalence area people biological communication pro vesicles immunotolerance nanosized biologics exosome alone enriched blood cell ischemia proprietary regenerative ucb pipeline company 150nm autoimmune types immunomodulatory exogenus clinical preconditioned innovative exosomes pioneer capacity agent exo diseases anti drug cord scientific unmet biomolecules generation treatments therapeutics active

Project "TEXAD" data sheet

The following table provides information about the project.

Coordinator	EXOGENUS THERAPEUTICS SA Organization address address: PARQUE BIOCANT NUCLEO 04 LOTE 2 city: CANTANHEDE postcode: 3060 197 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Portugal [PT]
Total cost	115˙000 €
EC max contribution	115˙000 € (100%)
Programme	1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
Code Call	H2020-INNOSUP-2019-02
Funding Scheme	CSA
Starting year	2019
Duration (year-month-day)	from 2019-12-30 to 2020-12-29

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	EXOGENUS THERAPEUTICS SA EXOGENUS THERAPEUTICS SA Organization address address: PARQUE BIOCANT NUCLEO 04 LOTE 2 city: CANTANHEDE postcode: 3060 197 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (CANTANHEDE)	coordinator	115˙000.00

Map

Project objective

Exogenus Therapeutics is a drug development company using an exosome-based platform technology to develop an innovative pipeline of therapeutic products. Exogenus’ scientific team has pioneer research work in the area of Umbilical Cord Blood (UCB)-derived Extracellular Vesicles (EVs) clinical application. Among EVs, exosomes are nanosized vesicles (30-150nm) released from all types of cells responsible for cell-to-cell communication. Exogenus’ technology makes use of UCB cells preconditioned in ischemia, which secrete EVs enriched in pro-regenerative, anti-inflammatory and immunomodulatory biomolecules. Based on immunomodulatory properties of the lead biological active agent under development (Exo-101), and its capacity to increase immunotolerance, the company is investigating the potential of these vesicles for the treatment of autoimmune diseases. There are more than 80 different autoimmune diseases (AD) and a prevalence of more than 50 million people in the US alone. There is a high unmet need for most of these diseases, especially regarding safer treatments with less secondary effects. Based on their proprietary vesicles derived from UCB, Exogenus aims to develop a new generation of biologics for AD, with high efficacy and less secondary effects.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TEXAD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TEXAD" are provided by the European Opendata Portal: CORDIS opendata.